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The use of generic drugs has been steadily increasing internationally as a result of economic pressure on drug budgets. 1 Generic drugs provide the opportunity for major savings in healthcare expenditure since they may be substantially lower in price than the innovator brands.
Prescribing drugs by their generic name and requesting pharmacists to dispense generic drugs are frequently suggested means for lowering the costs of health care. The practice of generic substitution is strongly supported by health authorities in many countries including Australia. 2 Australia's National Medicines Policy aims to 'meet medication and related needs, so that both optimal health outcomes and economic objectives are achieved for Australians'. 3 In response to the rising cost of the Pharmaceutical Benefits Scheme (PBS), the Australian Government has introduced policies to encourage the use of generic drugs. Probably the most significant of these to date have been the Brand Premium Policy (1990) and the Brand Substitution Policy (1994) . 4 Under the Brand Premium Policy, pharmaceutical manufacturers were allowed to set their own prices for the different brands of the same medicine. The Changes to prescribing software will further encourage the use of generics. Systems must now default to prescriptions allowing brand substitution. Doctors will still be able to select brand name drugs, but they will have to positively select for disallowing brand substitution. The government estimates that the change will save the government-funded PBS A$111 million over four years. 5 However, the potential for savings to the government through generic prescribing is limited because the government subsidy is linked to the 'benchmark' price.
The Australian Government has regulations to assure the quality, safety and efficacy of generic medicines. These include compliance with good manufacturing practice and the requirement that generic products must have demonstrated bioequivalence with the innovator brand, or the Australian market leader, before they can be listed on the PBS. 6 The quality use of medicines is central to the National Medicines nine brands available (Fig.1) . In some cases, the appearance of the drugs differs, adding to the problem of different brand names for the same drugs. Confusion could be greatly reduced if generic names of the drugs were required to be more prominent on the label than the 'brand' names. 'I'm a great believer in consumer participation because I believe that you get as much information (as you can) and get it from the appropriate people … I mean it is silly to go to a friend rather than my nephrologist. I consider all the information they are giving me and then balance it all to make a decision … hopefully an informed decision.' Achievement of optimal health outcomes and economic objectives requires participation, not just regulation.
